Developments for Ionis Pharmaceuticals after 1Q17


Jun. 13 2017, Updated 9:06 a.m. ET

Ionis’s recent developments

As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options.

Article continues below advertisement

Corporate developments

  • In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China.
  • In February 2017, Ionis and Akcea Therapeutics entered into a collaborative agreement with Novartis (NVS) for the development and commercialization of drugs AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx.

Drug developments

  • On June 1, 2017, Ionis announced that the European Commission had approved the drug Spinraza (nusinersen) for the treatment of spinal muscular atrophy. The drug was co-developed in collaboration with Biogen (BIIB).
  • On May 15, 2017, Ionis announced that NEURO-TTR, the phase III study evaluating the drug IONIS-TTR Rx (inotersen) for the treatment of patients with familial amyloid polyneuropathy, had met its primary endpoints.
  • On March 30, 2017, Akcea Therapeutics announced the initiation of a phase II study evaluating AKCEA-APO(a)-LRx for the treatment of patients with hyperlipoproteinemia and established cardiovascular disease.

To divest company-specific risks, investors could consider funds such as the VanEck Vectors Biotech ETF (BBH) which has a 1.1% exposure to Ionis Pharmaceuticals. BBH also has a 4.3% exposure to BioMarin (BMRN), a 6.9% exposure to Biogen (BIIB), and a 4.4% exposure to Incyte (INCY).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.